Sofosbuvir inhibits yellow fever virus in vitro and in patients with acute liver failure

Mendes, Érica Araújo; Pilger, Denise Regina Bairros de; Nastri, Ana Catharina de Seixas Santos; Malta, Fernanda de Mello; Pascoalino, Bruno dos Santos; D’Albuquerque, Luiz Augusto Carneiro; Balan, Andrea; Freitas, Lucio Holanda Gondim de; Durigon, Edison L.; Carrilho, Flair José; Pinho, João Renato Rebello

doi:10.1016/j.aohep.2019.09.001

Cited by 34 publications

(27 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The sample size calculation considered the estimated effect of sofosbuvir in YF-infected patients submitted to the compassionate use of this drug 7…”

Section: Methods and Analysismentioning

confidence: 99%

“…Another research team tested the in vitro activity against YF and zika virus of several antivirals used for hepatitis C virus (ribavirin, daclastavir, sofosbuvir and ledispavir/sofosbuvir combination). All the tested drugs presented activity and selectivity against YF and zika virus in human hepatoma cells, but ledispavir/sofosbuvir combination and sofosbuvir showed the best antiviral activity towards both viruses 7…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of sofosbuvir as treatment for yellow fever: protocol for a randomised controlled trial in Brazil (SOFFA study)

et al. 2019

Self Cite

View full text Add to dashboard Cite

IntroductionAn ongoing outbreak of yellow fever (YF) has been reported in Brazil with 1261 confirmed cases and 409 deaths since July 2017. To date, there is no specific treatment available for YF. Recently published papers describing in vitro and animal models suggest a potential effect of antiviral drugs (approved for the treatment of hepatitis virus) against flaviviruses, including YF. The primary aim of this study is to analyse the effect of sofosbuvir on viral kinetics and clinical outcomes among patients presenting with YF. This is a multicentre open-label randomised controlled trial with 1:1 individual allocation, stratified by severity and by recruiting centre.Methods and analysisAdults with suspected or confirmed YF infection and symptoms lasting up to 15 days are screened. Eligible and consenting patients are randomised to receive oral sofosbuvir 400 mg daily for 10 days or to receive standard clinical care. Viral kinetics are measured daily and the reduction in YF plasma viral load from the sample at inclusion to 72 hours after randomisation will be compared between active and control groups. Clinical outcomes include severity meeting criteria for intensive care support, liver transplantation, in-hospital mortality and mortality within 60 days.Ethics and disseminationEthics approval was obtained at the participating sites and at the national research ethics committee (CAAE 82673018.6.1001.0068). The trial has been submitted for ethical approval at additional potential recruiting centres. Results of the study will be published in journals and presented at scientific meetings.Trial registrationBrazilian Clinical Trials Registry (RBR-93dp9n).

show abstract

“…The sample size calculation considered the estimated effect of sofosbuvir in YF-infected patients submitted to the compassionate use of this drug 7…”

Section: Methods and Analysismentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Efficacy of sofosbuvir as treatment for yellow fever: protocol for a randomised controlled trial in Brazil (SOFFA study)

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Indeed, it has been developed for the positive-sense HCV RNA virus which shares high sequence and structural homology with SARS-CoV-2. Moreover, Sofosbuvir has been already shown to be effective for other positivesense RNA viruses, namely Yellow Fever and Hepatitis A virus [23,24].…”

Section: Journal Of Translational Medicinementioning

confidence: 99%

SARS-CoV-2 RNA polymerase as target for antiviral therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…gov NCT03891420). Recently, two YFV-infected patients presenting with acute liver failure were treated off-label with Sofosbuvir for a week as compassionate use and displayed marked reduction in viremia and improved liver function [99]. Furthermore, in recent years, virus-neutralizing monoclonal antibodies (mAbs) have also been recognized as a treatment modality for YF [100].…”

Section: Possible Role For Therapeutics In Yf Control?mentioning

confidence: 99%

Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever

Bifani

Ong

Alwis

2020

Curr Treat Options Infect Dis

View full text Add to dashboard Cite

At the turn of the nineteenth century, yellow fever (YF) was considered the most dangerous infectious disease with high case fatality. Subsequent, mass vaccination campaigns coupled with widespread elimination of the YF mosquito vector significantly decreased YF cases and reduced outbreaks to the tropical and subtropical forested regions of Africa and South America. However, recent (2016) large outbreaks in Angola, Democratic Republic of Congo (DRC), and SouthEastern Brazil, where previously had been demarcated as low-risk regions, have highlighted the possibility of a rapidly changing epidemiology and the potential re-emergence of yellow fever virus (YFV). Furthermore, the first-ever importation of YFV into Asia has highlighted the potential fear of YFV emerging as a global threat. In this review, we describe the changing epidemiology of YF outbreaks, and highlight the use of public health policies, therapeutics, and vaccination as tools to help eliminate future YFV outbreaks.

show abstract

Sofosbuvir inhibits yellow fever virus in vitro and in patients with acute liver failure

Cited by 34 publications

References 30 publications

Efficacy of sofosbuvir as treatment for yellow fever: protocol for a randomised controlled trial in Brazil (SOFFA study)

Efficacy of sofosbuvir as treatment for yellow fever: protocol for a randomised controlled trial in Brazil (SOFFA study)

SARS-CoV-2 RNA polymerase as target for antiviral therapy

Vaccination and Therapeutics: Responding to the Changing Epidemiology of Yellow Fever

Contact Info

Product

Resources

About